Oncology Corporate Profile
Merrion Pharmaceuticals is a publicly listed specialty pharmaceutical company engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion was established in 2003 to commercialise various technologies acquired from Elan Corporation, plc. Merrion's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Orazol® / MER-101||bisphosphonate (oral)||Adjuvant Breast cancer||III|
|Orazol® / MER-101||bisphosphonate (oral)||Bone metastases associated with Hormone refractory Prostate cancer (HRPC)||II|
|acyline / MER-104||GnRH antagonist (oral)||Prostate cancer||I|
View additional information on product candidates here »